First-line bevacizumab-containing therapy for breast cancer: Results in patients aged ≥70 years treated in the ATHENA study

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 111-118

  Biganzoli, L ^a   Di Vincenzo, E ^b   Jiang, Z ^c   Lichinitser, M ^d   Shen, Z ^e   Delva, R ^f   Bogdanova, N ^g   Vivanco, G L ^h   Chen, Z ⁱ   Cheng, Y ^j   Just, M ^k   Espie M ^l   Vinholes, J ^m   Hamm, C ⁿ   Crivellari, D ^o   Chmielowska, E ^p   Semiglazov, V ^q   Dalenc, F ^r   Smith, I ^s  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b Prato Hospital   (Italy)

^c Beijing 307 Hospital   (China)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e FUDAN UNIVERSITY   (China)

^f CENTRE PAUL PAPIN   (France)

^g Cancer Research Institute   (Russian Federation)

^h HOSPITAL DE CRUCES   (Spain)

ⁱ ANHUI MEDICAL UNIVERSITY   (China)

^j Jilin Provincial Hospital of Cancer   (China)

^k Internal Medicine Practice   (Germany)

^l SAINT LOUIS HOSPITAL   (France)

^m Oncology Clinic   (Brazil)

ⁿ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^o CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^p Regional Oncology Hospital   (Poland)

^q N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^r INSTITUT CLAUDIUS REGAUD   (France)

^s ROYAL MARSDEN HOSPITAL   (United Kingdom)

more..

Author keywords

Bevacizumab; Comorbidity; Elderly; First line; Metastatic breast cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

AGE DISTRIBUTION; AGED; AGING; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FEBRILE NEUTROPENIA; FISTULA; GENERAL CONDITION DETERIORATION; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METABOLIC ACIDOSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SEPSIS; SIDE EFFECT; SURVIVAL TIME; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

EID: 80052428282     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr043     Document Type: Article

References (23)

1. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
2. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
3. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab (B) for firstline treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [meeting abstracts]. J Clin Oncol 2009; 27 (Suppl): 15s. (Abstr 1005).
4. Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-4972.
5. Smith IE, Pierga J-Y, Biganzoli L et al. First-line bevacizumab plus taxanebased chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2011; 22: 595-602.
6. Ring A. The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer. Crit Rev Oncol Hematol 2010; 76: 127-132.
7. Schonberg MA, Marcantonio ER, Li D et al. Breast cancer among the oldest old: tumor characteristics, treatment choices and survival. J Clin Oncol 2010; 28: 2038-2045.
8. Protière C, Viens P, Rousseau F et al. Prescribers' attitudes toward elderly breast cancer patients. Discrimination or empathy? Crit Rev Oncol Hematol 2010; 75: 138-150.
9. Freyer G, Braud AC, Chaibi P et al. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol 2006; 17: 211-216.
10. Hamberg P, Verweij J, Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. Eur J Cancer 2007; 43: 1514-1528.
11. Silliman RA. When cancer in older adults is undermanaged: the breast cancer story. J Am Geriatr Soc 2009; 57 (Suppl 2): S259-S261.
12. Buist DS, Chubak J, Prout M et al. Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence. J Clin Oncol 2009; 27: 4508-4514.
13. Crivellari D, Aapro M, Leonard R et al. Breast cancer in the elderly. J Clin Oncol 2007; 25: 1882-1890.
14. Hancke K, Denkinger MD, König J et al. Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 2010; 21: 748-753.
15. O'Shaughnessy J, Dieras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC) [meeting abstracts]. Cancer Res 2009; 69 (Suppl): 512s (Abstr 207).
16. Glaspy J, Dieras V, Brufsky A et al. Bevacizumab in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer: PFS subgroup results from two phase III studies [meeting abstracts]. Eur J Cancer 2010; 8 (Suppl): 202 (Abstr 489).
17. Dieras V, Glaspy J, Brufsky A et al. Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [meeting abstracts]. Eur J Cancer 2009; 7 (Suppl): 265 (Abstr 5016).
18. Mancia G, De Backer G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
19. Hanson LC, Muss HB. Cancer in the oldest old: making better treatment decisions. J Clin Oncol 2010; 28: 1975-1976.
20. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
21. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
22. Richardson S, Dickler MN, Dang CT et al. Tolerance of bevacizumab in an older patient population: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience [meeting abstracts]. J Clin Oncol 2008; 26 (Suppl): (Abstr 9569).
23. Pivot X, Verma S, Thomssen C et al. Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study [meeting abstracts]. J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 1094).